Skip to main content

Extensively drug-resistant tuberculosis: experience at the Tuberculosis Research Centre, Chennai, India

Buy Article:

$55.58 + tax (Refund Policy)

Ten extensively drug-resistant tuberculosis (XDR-TB) patients were identi ed among 104 human immunode ciency virus negative multidrug-resistant tuberculosis (MDR-TB) patients treated at the Tuberculosis Research Centre, Chennai, India, in two different cohorts between 1999–2003 and 2006–2007. They were managed with individualised treatment regimens. At the time of diagnosis of MDR-TB, one patient had XDR-TB and three had initial o oxacin resistance. One patient who had had a lobectomy in addition to chemotherapy became bacteriologically negative, three died, three defaulted and the remaining three, who are bacteriologically positive, are still continuing treatment. Although based on a small number of patients, our results have not been encouraging.

Spanish
En el centro de investigación de Chennai, se detectaron 10 pacientes con tuberculosis extremadamente drogorresistente (TB-XDR) en los 104 pacientes negativos para el virus de la inmunode ciencia humana con tubercu losis multidrogorresistente (TB-MDR) tratados en este centro en dos cohortes diferentes del 1999 al 2003 y del 2006 al 2007. Estos pacientes recibieron pautas terapéuticas individualizadas. En el momento del diagnó stico de la TB-MDR, un paciente presentó TB- XDR y tres exhibieron resistencia inicial a o oxacino. Un pa ciente en quien se practicó una lobectomía además del tratamiento antituberculoso negativizó el esputo, tres pacientes fallecieron, hubo tres abandonos y los tres pacientes restantes, que siguen siendo bacteriológicamente positivos, continúan todavía el tratamiento. Si bien es cierto que el estudio se basa en una muestra pequeña, los resultados no son muy estimulantes.

French
On a identi é 10 patients atteints d'une tuberculose à germes ultrarésistants (TB-XDR) parmi 104 patients atteints d'une tuberculose à germes multirésistants (TBMDR) et séronégatifs pour le virus de l'immunodé cience humaine en traitement au Tuberculosis Research Centre à Chennai, dans deux cohortes différentes entre 1999–2003 et 2006–2007. Ils ont été pris en charge et soumis à des régimes de traitement individualisé. Au moment du diagnostic de TB-MDR, la TB-XDR existait chez un patient et une résistance initiale à l'o oxacine chez trois patients. Chez un patient qui a béné cié d'une lobectomie en plus de la chimiothérapie, l'examen bactériologique est devenu négatif, trois patients sont décédés, trois ont abandonné et les trois dont l'examen bactériologique reste positif sont toujours sous traitement. Bien qu'ils reposent sur un petit nombre de patients, nos résultats ne sont pas encourageants.

Keywords: DRUG RESISTANCE; MANAGEMENT; SECOND-LINE DRUGS; TUBERCULOSIS; XDR-TB

Document Type: Short Communication

Affiliations: Tuberculosis Research Centre (Indian Council of Medical Research), Chennai, India

Publication date: October 1, 2011

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content